



PATENT

Docket No. 2016-4005US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : RALPH M. STEINMAN, ET AL.
Serial No. : 09/073,596 Group Art Unit: 1644
Filed : May 6, 1998 Examiner: F. Pierre VanderVegt
For : METHOD FOR IN VITRO PROLIFERATION OF
DENDRITIC CELL PRECURSORS AND THEIR
USE TO PRODUCE IMMUNOGENS

AMENDMENT FEE TRANSMITTAL

COMMISSIONER OF PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application.

☐ No additional fee is required.

☒ The additional fee has been calculated as shown below:

CLAIMS AS AMENDED

	Claims • Remaining After Amendment		Highest No. Covered by Previous Payments	Present Extra	Rate	Additional Fee
Total*						
Claims	19	-	47	= 0	x \$18.00	<u>\$0.00</u>
Independent						
Claims	5	-	3	= 2	x \$78.00	<u>\$156.00</u>
Multiple Dependent Claim(s)	(If claims added by amendment include Multiple Dependent Claim(s) and there was not Multiple Dependent Claims(s) in application before amendment add \$260.00 to additional fee.)					<u>\$0.00</u>
Total:						<u>\$156.00</u>

* Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. § 1.75(c).



Docket No. 2016-4000 US5

- ☒ [X] Statement of "Small Entity" Status Under 37 CFR § 1.27 filed September 27, 1995.
Reduced Fees Under 37 CFR § 1.9(f) (50% of total) paid herewith. \$ 78.00.
- ☒ [X] Charge fee to Deposit Account No. 13-4500. Order No. 2016-4000US5.
A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ [X] The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for
this amendment, including all fees pursuant to 37 C.F.R. § 1.17 for its timely consideration, or credit any
overpayment to Deposit Account No. 13-4500. Order No. 2016-4000US5. A DUPLICATE COPY OF
THIS SHEET IS ATTACHED.
- ☐ [] Page(s) of substitute Sequence Listing
- ☐ [] Computer disk(s) containing substitute Sequence Listing
- ☐ [] Statement under 37 C.F.R. § 1.825(b) that the computer and paper copies of the substitute Sequence Listing
are the same.
- ☐ [] A check in the amount of \$ to cover the filing fee is attached.

RECEIVED


OCT 16 2000

TECH CENTER 1800/2900

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

By:


Kenneth H. Sonnenfeld
Reg. No. 33, 285

Dated: September 27, 2000

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: AMD-TRAN.NY
Rev. 11/13/98



[Handwritten signature]
PATENT

2016-4000US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : RALPH M. STEINMAN, ET AL.
Serial No. : 09/073,596 Group Art Unit: 1644
Filed : May 6, 1998 Examiner: F. Pierre Vandervegt
For : METHOD FOR IN VITRO PROLIFERATION OF DENDRITIC CELL
PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

This is response to the Office Action dated March 27, 2000 in the above-identified application. Applicants have petitioned and paid the appropriate fee under 37 C.F.R. §1.136 to extend the time to respond to the Office Action by three months, up to and including September 27, 2000.

Claims 82-100 are pending in the application. Claims 86-88, 90-93, 98, and 100 stand withdrawn as relating to a non-elected group. Claims 82-85, 89, 94-97 and 99 stand rejected.

10/05/2000 ZHONTES 00000015 134500 09073596

02 FC:102 156.00 CH

Please amend the application as follows:

IN THE CLAIMS

[Handwritten: 82-100]
82 (amended). An [A] in vitro composition comprising an enriched population of
[isolated] proliferating dendritic cell precursors in the presence of GM-CSF.